|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007634,
umls-concept:C0030274,
umls-concept:C0033085,
umls-concept:C0034693,
umls-concept:C0034721,
umls-concept:C0061355,
umls-concept:C0086418,
umls-concept:C0205314,
umls-concept:C0243071,
umls-concept:C0542341,
umls-concept:C0678594,
umls-concept:C0679622,
umls-concept:C1515655,
umls-concept:C1533691,
umls-concept:C2700303,
umls-concept:C2716826
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-2-23
|
|
pubmed:abstractText |
Glucagon-like peptide-1 (GLP-1) has protective effects on pancreatic ?-cells. We evaluated the effects of a novel, long-acting human GLP-1 analogue, taspoglutide, on ?-cells in vitro and in vivo.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1463-1326
|
|
pubmed:author |
pubmed-author:BénardeauAA,
pubmed-author:BoscoDD,
pubmed-author:BrecheisenMM,
pubmed-author:MiglioriniCC,
pubmed-author:PrummerMM,
pubmed-author:SebokovaEE,
pubmed-author:SewingSS,
pubmed-author:TobalinaLL,
pubmed-author:UhlerRR,
pubmed-author:WangHH,
pubmed-author:WollheimC BCB
|
|
pubmed:copyrightInfo |
© 2011 Blackwell Publishing Ltd.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
326-36
|
|
pubmed:meshHeading |
pubmed-meshheading:21205124-Animals,
pubmed-meshheading:21205124-Apoptosis,
pubmed-meshheading:21205124-Cells, Cultured,
pubmed-meshheading:21205124-Deoxyuridine,
pubmed-meshheading:21205124-Diabetes Mellitus, Type 2,
pubmed-meshheading:21205124-Glucagon-Like Peptide 1,
pubmed-meshheading:21205124-Humans,
pubmed-meshheading:21205124-Immunohistochemistry,
pubmed-meshheading:21205124-Insulin-Secreting Cells,
pubmed-meshheading:21205124-Male,
pubmed-meshheading:21205124-Peptides,
pubmed-meshheading:21205124-Rats,
pubmed-meshheading:21205124-Rats, Zucker,
pubmed-meshheading:21205124-Receptors, Glucagon
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Taspoglutide, a novel human once-weekly GLP-1 analogue, protects pancreatic ?-cells in vitro and preserves islet structure and function in the Zucker diabetic fatty rat in vivo.
|
|
pubmed:affiliation |
F. Hoffmann-La Roche AG, Grenzacherstrasse 124, Basel, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
